Protagonist Therapeutics (PTGX) EBIAT (2017 - 2025)
Historic EBIAT for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.
- Protagonist Therapeutics' EBIAT fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7312.89%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' EBIAT is -$39.3 million, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' EBIAT ranged from a high of $207.3 million in Q1 2024 and a low of -$41.0 million during Q2 2022
- Its 5-year average for EBIAT is -$7.5 million, with a median of -$33.2 million in 2024.
- As far as peak fluctuations go, Protagonist Therapeutics' EBIAT tumbled by 33545.02% in 2021, and later skyrocketed by 71479.61% in 2024.
- Quarter analysis of 5 years shows Protagonist Therapeutics' EBIAT stood at -$36.9 million in 2021, then grew by 7.35% to -$34.2 million in 2022, then surged by 179.94% to $27.3 million in 2023, then surged by 381.7% to $131.7 million in 2024, then crashed by 129.88% to -$39.3 million in 2025.
- Its last three reported values are -$39.3 million in Q3 2025, -$34.8 million for Q2 2025, and -$11.7 million during Q1 2025.